April 2014, Part 1

The New Generation of Immunotherapies A Focus on the PD-1 Pathway

It is becoming increasingly evident that cancer is a highly heterogeneous disorder. Researchers have begun to recognize that cancer progression is affected not just by genetic mutations, but by the interaction between tumors and the microenvironment in which they thrive. The evolution in understanding tumor biology and genetics has helped [ Read More ]

Matthew Welding, MPH

Introduction

Checkpoint Inhibition of PD-1: The Promise of Pembrolizumab (MK-3475) and Beyond

The idea of harnessing a patient’s own defenses and actively augmenting a deficient immune response to help fight disease has been implemented since the 18th century. Adoption of immunotherapy into clinical practice has been difficult until recently, when many late-stage clinical trials demonstrating an overall survival (OS) advantage in melanoma [ Read More ]

Zeynep Eroglu, MD

Immunotherapy

Review: The Role of the PD-1 Pathway in Immunotherapy

For decades, chemotherapy, radiation therapy, and excisional surgery have served as the mainstays of cancer treatment. While often effective, these treatments affect healthy as well as neoplastic cells and therefore cause many unintended side effects, some of which may be life-threatening. Even after treatment, a substantial proportion of patients experience [ Read More ]

Immunotherapy

Sequential Therapy for Renal Cell Carcinoma

With several agents now approved and broadly available for the treatment of patients with advanced renal cell carcinoma (RCC), a great deal of attention has been focused on determining the most appropriate sequence of therapies. The concept of sequential therapy has developed for several reasons, including: (1) the availability of [ Read More ]

Daniel C. Cho, MD

Sequential Therapy

Introducing Immunotherapy in Oncology: A 4-Part Supplement Series to Personalized Medicine in Oncology

Dear Colleague, Personalized Medicine in Oncology (PMO) is proud to present a 4-part supplement series to our reading community focused on the timely issue of immunotherapy and its role in personalizing cancer care. Harnessing the power of the immune system to combat cancer is not a new idea; however, the [ Read More ]

Sanjiv S. Agarwala, MD